MegaPro Biomedical Co., Ltd (6827.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$14.05 (-12.73%) as of
Key statistics
- Market cap
- 1.11B
- EPS (TTM)
- -1.31
- Dividend yield
- 0.00%
- 52-week range
- 9.47 – 17.85
- Profit margin
- 0.00%
- Volume
- 1.94M
About MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.